

Fetal Growth Restriction

Purpose: To provide guidelines for screening and management of fetal growth restriction (FGR) complicating pregnancy.

1. Definition:

- FGR: fetus with an estimated fetal weight (EFW) or an abdominal circumference (AC) less than 10th percentile for gestational age.
 - o **Severe FGR: If EFW or AC < 3rd percentile.**

It is important to differentiate 2 different entities: FGR and small for gestational age (SGA). FGR is due to a pathological process. The fetus has not attained its biologically determined growth potential. SGA (small for gestational age) describes a newborn whose birthweight is less than the 10th percentile for gestational age. It is a postnatal diagnosis.

Hadlock formula was found to be more accurate in the overall estimation of fetal weight, and it is recommended population-based reference to determine fetal weight percentiles.

2. Classification:

- Early onset FGR: diagnosed 32 weeks before (30%). It is more severe and follows an established pattern of Doppler deterioration. It is highly associated with hypertensive disorders and placental insufficiency.
- Late onset FGR: diagnosed at or after 32 weeks (70%). It is milder in presentation.
- .

Differentiation between asymmetric and symmetric using HC/AC has not been found to be an independent predictor of adverse pregnancy outcomes.

3. Etiology:

Table 1. Etiology of FGR

Maternal factors	Fetal factors	Placental factors
Demographics: Extremes of maternal age Race Low pre-pregnancy weight Poor maternal weight gain Obstetrical: Short inter-pregnancy interval	Genetic: Trisomy 21, 18, 13 Turner syndrome Deletion of chromosomes 4, 5 Genetic syndromes Congenital malformations: Congenital heart disease Abdominal wall defect	Placenta: Placental abruption Placental infarction Circumvallate placenta Confined placental mosaicism Placental hemangioma Placental chorioangioma Fetal villous obliteration

SHMG Maternal Fetal Medicine has developed these guidelines as a reference tool to assist referring physicians. Obstetric medical needs are complex, and these guidelines may not apply in every case. Treating clinicians should exercise their own professional medical judgment regarding the appropriate treatment and management of their patients. Treating clinicians are solely responsible for confirming the accuracy, timelines, completeness, appropriateness, and helpfulness of this material in making all medical, diagnostic, or prescription decisions.

Prior history of SGA Behavioral/environmental: Smoking Alcohol Drug use High altitude Systemic disease: Hypertension Pregestational diabetes Renal Disease Anemia Pulmonary disease Congenital heart disease Autoimmune disease Antiphospholipid syndrome GI disease Malnutrition Transplant recipient (renal) Others: Artificial reproductive technology Uterine factors Medications Angiotensin gene mutation	Anencephaly Infection: TORCH Malaria Chlamydia, Mycoplasma, Listeria, TB Others: Multiple pregnancy	Umbilical cord: Velamentous cord insertion Single umbilical artery
---	---	--

4. Workup:

- Confirm pregnancy dating
- Detailed medical history: to evaluate any disease or risk factor associated with FGR (refer to Table above).
- Targeted anatomy survey (CPT code 76811) by Maternal Fetal Medicine.
- Fetal echocardiogram if suboptimal visualization of the heart on targeted US.
- Offer diagnostic testing including chromosomal microarray analysis (CMA) when FGR and a fetal malformation, polyhydramnios or both are present. Offer CMA for unexplained isolated FGR if diagnosed < 32 weeks.
- Polymerase chain reaction (PCR) for CMV in patients with unexplained FGR who elect amniocentesis.
- Recommend against serology for toxoplasmosis, CMV, rubella or herpes in the absence of other risk factors.
- **Maternal work up for preeclampsia: baseline CBC, CMP, and protein: creatinine ratio.**
- Recommend serial Umbilical Artery Doppler assessment to evaluate for deterioration.

SHMG Maternal Fetal Medicine has developed these guidelines as a reference tool to assist referring physicians. Obstetric medical needs are complex, and these guidelines may not apply in every case. Treating clinicians should exercise their own professional medical judgment regarding the appropriate treatment and management of their patients. Treating clinicians are solely responsible for confirming the accuracy, timelines, completeness, appropriateness, and helpfulness of this material in making all medical, diagnostic, or prescription decisions.

5. Management:

Table 2. Surveillance

FGR: EFW or AC 3-9 th %ile	Severe FGR: EFW or AC < 3 rd %ile
- Fetal growth q 3 weeks - UA Doppler weekly - BPP at 26 weeks - NST weekly (starting at 28 weeks)	- Fetal growth q 2 weeks - UA Doppler weekly - BPP at 26 weeks - NST weekly (starting at 28 weeks)

6. Umbilical Artery Doppler interpretation & management: (obtain minimum 3 waveforms/measurements) UA Doppler evaluation should be performed in any fetus with FGR.

Elevated SD ratio, PI, or RI >95 th percentile	Absent end diastolic flow (AEDF) and intermittent AEDF	Reverse end diastolic flow (REDF)
- Weekly AFI/UA Doppler - BPP weekly at diagnosis - Add weekly NST at 28 weeks	- Admit to hospital for monitoring, consult MFM - Administer steroids for fetal lung maturity - AFI/UA Doppler two or three times per week - Twice daily NST - Manage inpatient	- Admit to hospital for monitoring, consult MFM - Recommend continuous monitoring - If FHR tracing is reassuring, consider twice daily NST - Administer steroids for fetal lung maturity - AFI/UA Doppler daily or every other day - Manage inpatient - Deliver for non-reassuring fetal status or 24 hours after completion of steroid course depending on gestational age

7. Timing of delivery


- FGR:** EFW or AC 3-9th percentile with normal AFI/UA Doppler (SD ratio, PI, or RI < 95th percentile): Deliver at 38-39 weeks. If EFW or AC 3-9th percentile with **elevated** UA Doppler (SD ratio, PI, or RI at or > 95th percentile): Deliver at 37 weeks.
- Severe FGR:** EFW or AC < 3rd with normal AFI and normal or increased UA Doppler (SD ratio, PI, or RI < or > 95th percentile): Deliver 37 weeks.

SHMG Maternal Fetal Medicine has developed these guidelines as a reference tool to assist referring physicians. Obstetric medical needs are complex, and these guidelines may not apply in every case. Treating clinicians should exercise their own professional medical judgment regarding the appropriate treatment and management of their patients. Treating clinicians are solely responsible for confirming the accuracy, timelines, completeness, appropriateness, and helpfulness of this material in making all medical, diagnostic, or prescription decisions.

- c. **FGR with AEDF or oligohydramnios:** Deliver at 33 to 34 weeks or for non-reassuring testing.
- d. **FGR with REDF:** Deliver 24 hours after completion of steroid course with reassuring fetal testing or immediately for non-reassuring fetal testing. Deliver at 30-32 weeks.
- e. Consider delivery for no interval growth of the fetus.
- f. Pregnancies with **FGR complicated by A/REDV, cesarean delivery** should be considered based on the entire clinical scenario.
- g. Recommend antenatal corticosteroids if delivery is anticipated before 33 6/7 weeks of gestation or for pregnancies between 34 0/7 and 36 6/7 weeks of gestation in women without contraindications who are at risk of preterm delivery within 7 days and who have not received a prior course of antenatal corticosteroids.
- h. Magnesium sulfate for fetal and neonatal neuroprotection for women with pregnancies that are less than 32 weeks of gestation in whom delivery is likely.

Proposed algorithm for management of FGR (see below)

Proposed algorithm for management of FGR:



SHMG Maternal Fetal Medicine has developed these guidelines as a reference tool to assist referring physicians. Obstetric medical needs are complex, and these guidelines may not apply in every case. Treating clinicians should exercise their own professional medical judgment regarding the appropriate treatment and management of their patients. Treating clinicians are solely responsible for confirming the accuracy, timelines, completeness, appropriateness, and helpfulness of this material in making all medical, diagnostic, or prescription decisions.